Paul Hartmann AGSTU:PHH2 61 Days Payable is 108.66 as of Dec. 2025, which is 34% above its 10-year median of 80.89. GuruFocus rates STU:PHH2 with a GF Score™ of 61/100 and a GF Value™ of €225.24 (Fairly Valued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 66.79% on this metric.
The historical rank and industry rank for Paul Hartmann AG's Days Payable or its related term are showing as below:
STU:PHH2'
s Days Payable Range Over the Past 10 Years
Min: 55.03 Med: 80.89 Max: 103.97
Current: 103.97
During the past 13 years, Paul Hartmann AG's highest Days Payable was 103.97. The lowest was 55.03. And the median was 80.89.
STU:PHH2's Days Payable is ranked better than 66.79% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs STU:PHH2: 103.97
Paul Hartmann AG's Days Payable
declined
from Dec. 2024 (113.98) to Dec. 2025 (108.66).
It may suggest that Paul Hartmann AGaccelerated paying its suppliers.
Paul Hartmann AG Days Payable Related Terms
Paul Hartmann AG Days Payable Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PHH2 vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Paul Hartmann AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (STU:PHH2) has a Days Payable of 108.66 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Paul Hartmann AG and its competitors. This is 34% above median its historical median of 80.89. Over the past decade, Paul Hartmann AG's Days Payable has ranged from 55.03 to 103.97. According to the industry distribution chart, Paul Hartmann AG ranks #264 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 33.2%.
Is Paul Hartmann AG's Days Payable too high?
Paul Hartmann AG's current Days Payable of 108.66 is 34% above median its 10-year median of 80.89. Over the past 10 years, this metric has ranged from a low of 55.03 to a high of 103.97. The Medical Devices & Instruments industry median Days Payable is 68.07. Paul Hartmann AG's value of 108.66 is 59.6% above this industry median. Based on the distribution chart, Paul Hartmann AG ranks #264 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #264 out of 795 companies for Days Payable. This puts Paul Hartmann AG in the upper half of its industry. The industry median Days Payable is 68.07. Paul Hartmann AG's value of 108.66 is 59.6% above this benchmark. Historically, Paul Hartmann AG's own Days Payable has ranged from 55.03 to 103.97 over the past decade. While the company's 10-year median is 80.89 vs. the industry median of 68.07, Paul Hartmann AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current Days Payable of 108.66 is 59.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current Days Payable is 108.66, which is 34% above median its own 10-year median of 80.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Fairly Valued. The stock's GF Value™ is €225.24, compared to a current price of €204.00 — trading 9.4% below its estimated fair value. The current Days Payable is 108.66, which is 34% above median its 10-year median of 80.89 and 59.6% above the Medical Devices & Instruments industry median of 68.07. Paul Hartmann AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current Days Payable is 108.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €204.00 is trading 9.4% below its estimated GF Value™ of €225.24.
GuruFocus considers Paul Hartmann AG to be Fairly Valued.
Key valuation signals for STU:PHH2:
Days Payable: 108.66 (34% above median its 10-year median of 80.89)
GF Value™: €225.24 vs. price of €204.00 (9.4% below fair value)
Industry Position: 59.6% above the Medical Devices & Instruments median (#264 of 795)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
61GF Score
Get the complete analysis for STU:PHH2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
